

DETAILED PROGRAM

MONDAY, DECEMBER 6, 2021

12:00 PM - 5:00 PM CT

REGISTRATION – Main Lobby

5:30 PM - 7:00 PM CT

Metastatic Breast Cancer Heroes™ 2021

<https://event.curetoday.com/event/c6cdbe06-fa54-4571-a364-b8cca53b5800/summary>

TUESDAY, DECEMBER 7, 2021

7:45 AM - 8:00 AM CT

WELCOME AND OPENING REMARKS – Hall 3

Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

8:00 AM - 10:45 AM CT

GENERAL SESSION 1 – Hall 3

Co-Moderator: Matthew J. Ellis, MB, BChir, BSc, PhD, FRCP
Baylor College of Medicine
Houston, TX

and
Co-Moderator: Jenny Chang, MD, MB BChir
Houston Methodist Hospital
Houston, TX

8:00 AM CT

GS1-00 Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial

Bianchini G, Wang XQ, Danenberg E, Huang C-S, Egle D, Callari M, Bermejo B, Zamagni C, Thill M, Anton A, Dugo M, Zambelli S, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Györffy B, Biasi O, Valagussa P, Viale G, Gianni L, Ali HR. San Raffaele Scientific Institute, Milano, Italy; CRUK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom; National Taiwan University Hospital and Taiwan Breast Cancer Consortium, Taipei, Taiwan; Department of Gynecology, BrustGesundheitZentrum Tirol, Medical University Innsbruck, Innsbruck, Austria; Hospital Clínico Universitario Valencia and GEICAM, Valencia, Spain; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany; Hospital Universitario Miguel Servet and GEICAM, Zaragoza, Spain; Ospedale Santa Maria della Misericordia, Udine, Italy; Hospital Universitario 12 de octubre, Madrid, Spain; Illrd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute-CCCIT;

Cancer Cluster Salzburg, Salzburg, Austria; NN Petrov Research Inst of Oncology, St. Petersburg, Russian Federation; IRCCS Istituto Europeo di Oncologia, Milano, Italy; Cancer Trials Ireland & Mater Misericordiae University Hospital, Dublin, Ireland; Istituto Nazionale Tumori, Milano, Italy; Università degli Studi di Genova, Ospedale Policlinico San Martino, Genova, Italy; Ospedale San Raffaele, Milano, Italy; Fondazione Michelangelo, Milano, Italy; University of Milan, Istituto Europeo di Oncologia IRCCS, Milano, Italy.

8:15 AM CT**GS1-01 KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early-stage high-risk triple-negative breast cancer (TNBC)**

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Hee Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier M-A, Im S-A, Ahn J-H, Gion M, Baron-Hay S, Boileau J-F, Zhu Y, Pan W, Tryfonidis K, Karantza V, O'Shaughnessy J. Barts Cancer Institute, Queen Mary University London, London, United Kingdom; International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain and Vall d'Hebron Institute of Oncology, Barcelona, Spain; National Cancer Center Singapore, Duke-NUS Medical School, Singapore, Singapore; Yale School of Medicine, Yale Cancer Center, New Haven, CT; Cedars-Sinai Medical Center, Los Angeles, CA; Kliniken Essen-Mitte, Essen, Germany; Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer theme, Karolinska University Hospital, Solna, Sweden; Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany; Hokkaido Cancer Center, Sapporo, Japan; Breast Cancer Center, HELIOS Klinikum Berlin-Buch GmbH, Berlin, Germany; University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; Compass Oncology, US Oncology, Portland, OR; Texas Oncology, Austin, TX; Virginia Oncology Associates, Norfolk, VA; Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, Portugal; Centre Jean-Perrin, Clermont-Ferrand, France; Seoul National University, Seoul, Republic of Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Ramon y Cajal University Hospital, Madrid, Spain; Royal North Shore Hospital, Sydney, NSW, Australia; McGill University, Jewish General Hospital Segal Cancer Centre, Montréal, QC, Canada;; Merck & Co., Inc., Kenilworth, NJ; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX.

8:30 AM CT**GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer**

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MMd, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P. International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Princess Margaret Cancer Centre, Toronto, ON, Canada; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Maria

Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Seoul National University Hospital, Seoul, Republic of Korea; Pantai Hospital, Kuala Lumpur, Malaysia; Arturo Lopez Perez Foundation, Santiago, Chile; Republican Clinical Oncology Dispensary, Republic of Bashkortostan, Russian Federation; Centro de Hematologia e Oncologia, Porto Alegre, Brazil; International Breast Cancer Center, Quiron Group, Barcelona, Spain; Aichi Cancer Center Hospital, Nagoya, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Oncomedica S.A., Monteria, Colombia; Ege University Medical Faculty, Izmir, Turkey; Peter McCallum Cancer Institute, Melbourne, Australia; Merck & Co., Inc., Kenilworth, NJ; Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, United Kingdom.

8:45 AM CT

GS1-03 Discussant

Hope S. Rugo, MD
University of California San Francisco
San Francisco, CA

9:00 AM CT

GS1-04 Moved to Wednesday, Dec 8 GS2-00.

9:15 AM CT

GS1-05 Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

Krop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, Lisberg AE, Kogawa T, Papadopoulos KP, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F, Bardia A. Dana-Farber Cancer Institute, Boston, MA; Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center Harvard Medical School, Boston, MA; National Cancer Center Hospital, Tokyo, Japan; NEXT Oncology, San Antonio, TX; Virginia Cancer Specialists, Fairfax, VA; Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA; Advanced Medical Development Center, Cancer Institute Hospital of JFCR, Tokyo, Japan; START Center for Cancer Care San Antonio, San Antonio, TX; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Daiichi Sankyo Inc, Basking Ridge, NJ; Daiichi Sankyo Co, Ltd, Tokyo, Japan.

9:30 AM CT
GS1-06 A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer

Xu B, Zhang Q, Hu X, Li Q, Sun T, Li W, Ouyang Q, Wang J, Tong Z, Yan M, Li H, Zeng X, Shan C, Wang X, Yan X, Zhang J, Zhang Y, Wang J, Zhang L, Lin Y, Feng J, Chen Q, Huang J, Lu Y, Li H, Wu J, Cheng J, Hao Y, Geng C, Lu M, Li Y, Chen X, Song L, Wu X, Hu C, Wu X, Wang X, Pan Y, Cui Y, Guohua Yu, Sun S. Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China; Harbin Medical University Cancer Hospital, Harbin, China; Fudan University Shanghai Cancer Center, Shanghai, China; Liaoning Cancer Hospital & Institute, Liaoning, China; The First Hospital of Jilin University, Jilin, China; Hunan Cancer Hospital, Changsha, China; Linyi Cancer Hospital, Shandong, China; Tianjin Medical University Cancer Institute & Hospital, Tianjin, China; Henan Cancer Hospital, Zhengzhou, China; Beijing Cancer Hospital, Beijing, China; Chongqing University Cancer Hospital, Chongqing, China; Affiliated Hospital of Jining Medical University, Jining, China; Run Run Shaw Hospital, Affiliated Hospital of Zhejiang University, Hangzhou, China; West China Hospital, Sichuan University, Chengdu, China; The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Jiangsu Cancer Hospital, Nanjing, China; Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, China; The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Guangxi Medical University Cancer Hospital, Guangxi, China; Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China; The First Affiliated Hospital of Hainan Medical University, Haikou, China; Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China; The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning, China; The Fourth Hospital of Hebei Medical University and Hebei Cancer Hospital, Shijiazhuang, China; Beijing Shijitan Hospital, Capital Medical University, Beijing, China; Fuzhou General Hospital, Fuzhou, China; Shandong Cancer Hospital, Jinan, China; Taizhou EOC Pharma Co., Ltd., Taizhou, China; Anhui Provincial Cancer Hospital, Hefei, China; Hubei Cancer Hospital, Wuhan, China; Zhejiang Cancer Hospital, Hangzhou, China; Anhui Provincial Hospital, Hefei, China; Zhongshan Hospital, Fudan University, Shanghai, China; Weifang People's Hospital, Weifang, China; Xuzhou Central Hospital, Xuzhou, China.

9:45 AM CT
GS1-07 Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial

Gnant M, Dueck AC, Frantal S, Martin M, Burstein H, Greil R, Fox P, Wolff AC, Chan A, Winer E, Singer C, Miller K, Colleoni M, Naughton M, Rubovszky G, Bliss J, Mayer IA, Steger GG, Nowecki Z, Hahn O, Wolmark W, Rugo H, Pfeiler G, Fohler H, Metzger O, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A*, and Mayer EL **shared last authorship*. Medical University of Vienna, Vienna, Austria; Alliance Statistics and Data Center, Mayo Clinic, Phoenix, AZ; ABCSG, Vienna, Austria; Hospital General Universitario Gregorio Marañón, Madrid, Spain; Dana-Farber Cancer Institute, Boston, MA; Salzburg Cancer Research Institute– Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR) Paracelsus Medical University, Salzburg, Austria; Central West Cancer Care Centre, Orange Health Service, Orange; NSW, Australia; Johns Hopkins University, Baltimore, MD; Breast Cancer Research Centre

-WA, Perth, Australia; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN; IEO, European Institute of Oncology, IRCCS, Milan, Italy; The Ohio State University, Columbus, OH; National Institute of Oncology, Budapest, Hungary; The Institute of Cancer Research, London, United Kingdom; Vanderbilt University, Nashville, TN; The Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; University of Chicago, Chicago, IL; NSABP/NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; BIG, Brussels, Belgium; Pfizer, Cambridge, MA; Pfizer, La Jolla, CA; Mayo Clinic, Rochester, MN; University of Pennsylvania, Philadelphia, PA.

10:00 AM CT

GS1-08 CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438)

Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey RR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. Mount Sinai Hospital/Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, ON, Canada; Canadian Cancer Trials Group, Queens University, Kingston, ON, Canada; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada; Applied Statistician, Toronto, ON, Canada; CHU de Quebec, University Laval, Quebec City, QC, Canada; Dana Farber Cancer Center, Harvard University, Boston, MA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY; Vanderbilt University, Nashville, TN; Mayo Clinic, Rochester, MN; Institute of Cancer Research, London, United Kingdom; NRG Oncology, University of Pittsburgh, Pittsburgh, PA; IBCSG, Department of Oncology, University of Bern, Berne, Switzerland; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Vanderbilt-Ingram Cancer Center, Nashville, TN; British Columbia Cancer Agency, University of British Columbia, Surrey, BC, Canada; James Cancer Hospital and the Ohio State University Comprehensive Cancer Center, Columbus, OH; Baylor College of Medicine, Houston, TX; CRTCU, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom; Princess Margaret Cancer Center, University Health Network, Dept of Medical Biophysics, University of Toronto, Toronto, ON, Canada.

10:15 AM CT

GS1-09 Inhibition of GPX4 induces preferential death of p53-mutant triple-negative breast cancer cells

Tahaney WM, Qian J, Powell R, Moyer CL, Ma Y, Nguyen N, Hill J, Stephan C, Mazumdar A, Davies PJA, Brown PH. Baylor College of Medicine, Houston, TX; UT MD Anderson Cancer Center, Houston, TX; Texas A&M Institute for Biosciences and Technology, Houston, TX.

10:30 AM CT

GS1-10 Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIRO2-BREAST

André F, Gonçalves A, Filleron T, Dalenc F, Lusque A, Campone M, Sablin M-P, Bonnefoi H, Bieche I, Lacroix L, Tran-Dien A, Jimenez M, Jacquet A, Wang Q, Rouleau E, Gentien

D. Soubeyran I, Morel A, Arnedos M, Bachelot T. Gustave Roussy-Department of Medical Oncology, Villejuif, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; Institut de Cancérologie de l'Ouest, ST-HERBLAIN, France; Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Institut Curie and Paris-Descartes University-Department of Medical Oncology, Paris, France; Gustave Roussy-Department of Medical Biology and Pathology, BMO Unit - AMMICA UMS3655/US23, Villejuif, France; Gustave Roussy Cancer Campus-Inserm UMR981 and Department of Medical Oncology, Villejuif, France; Unicancer, Paris, France; Centre Léon Bérard-Département de Recherche Translationnelle et d'Innovation, Lyon, France; Institut Curie-Genomics Platform, Translational Research Department. PSL University, Paris, France; Institut Bergonié-nité de Pathologie Moléculaire - Département de Biopathologie, Bordeaux, France; ICO- Centre Paul Papin-Department of Innate Immunity and Immunotherapy, Angers, France; Centre Léon Bérard-Department of Medical Oncology, Lyon, France

10:00 AM - 5:00 PM CT
EXHIBITS – Hall 2

10:45 AM - 11:00 AM CT
BREAK

11:00 AM - 1:00 PM CT
COVID-19 and Cancer - Hall 4A

Sub-Session: Living in the COVID generation – Vaccinations and Patient Perspectives

Moderator: Susan Rafte
Community Advocate Baylor College of Medicine
Houston, MD

Peter Hotez, MD
Baylor College of Medicine
Houston, TX

Patient Advocates

Abigail Johnston
Sharon Anderson
Isabel Centeno

Sub-Session: How COVID changed “everything”

Moderator: Melissa L. Bondy, PhD
Stanford Medicine
Stanford, CA

How COVID changed cancer center operations

Debra Patt, MD, PhD
Texas Oncology
Austin, TX

How COVID changed clinical trials

Ko Un (Clara) Park, MD
The Ohio State University
Columbus, OH



How COVID changed regulatory aspects

Donna Rivera, PharmD
US Food & Drug Administration
Baltimore, MD

Sub-Session: Impact of COVID across Cancer Continuum

Moderator: Ko Un (Clara) Park, MD
The Ohio State University
Columbus, OH

Challenges in breast cancer supportive care during COVID 19 and beyond

Maryam Lustberg, MD, MPH
Yale University School of Medicine
New Haven, CT

Importance of real world data in fighting a pandemic

Dimpy Shah, MD, PhD
UT Health San Antonio
San Antonio, TX

The impact of the COVID-19 outbreak on breast cancer stage in the Netherlands by screening status

Anouk H. Eijkelboom, PhD
Netherlands Comprehensive Cancer Organization
Utrecht, Netherlands

National claims data analysis of breast cancer diagnosis and treatment before versus during the COVID-19 pandemic

Jennifer L. Caswell-Jin, MD
Stanford University
Stanford, CA

**11:00 AM - 1:00 PM CT
WORKSHOPS**

Clinical Research: From Study Design to Scientific Presentation – Stars at Night Ballroom 1&2

Moderator: Aditya Bardia, MD, MPH
Massachusetts General Hospital
Boston, MA

Selecting rational biomarkers for clinical and translational studies

Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

How to design an efficient clinical study

Valentina Nekljudova, PhD
German Breast Group
Neu Isenburg, German

How to include patient advocates in clinical research

Patty Spears, BS
University of North Carolina at Chapel Hill
Chapel Hill, NC

How to present clinical research results effectively

George W. Sledge, Jr, MD
Stanford University School of Medicine
Stanford, CA

Basic Workshop: Basic Science for Breast Oncologists – Stars at Night Ballroom 3&4

Moderator: Alana Welm, PhD
University of Utah Huntsman Cancer Institute
Salt Lake City, UT

Genome editing in human organoids as new models for discovery

Jennifer Rosenbluth, MD, PhD
University California San Francisco
San Francisco, CA

In silico experimentation from your living room: Tools to access and analyze existing datasets

Daniel Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH

Tricking T cells into action: Using patient-derived organoids to identify and expand tumor-specific T cells

Senthil K. Muthuswamy, PhD
Beth Israel Deaconess Medical Center
Boston, MA

Meeting the bar: How to tell when basic science discoveries are ready to translate

Bora Lim, MD
UT MD Anderson Cancer Center
Houston, TX

1:00 PM - 4:00 PM CT

SPECIAL SESSION – Hall 3

Trust in Science and Healthcare

Co-Moderator: Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC
and
Co-Moderator: Maimah Karmo
Tigerlily Foundation
Stone Ridge, VA

Keynote #1

Lori L. Wilson, MD
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Panel 1: Equity in Research and Patient Care

Deborah Stroman, PhD, CLU
UNC and Project Ground Water
Chapel Hill, NC



Olufunmilayo I. Olopade, MD, FACP
University of Chicago
Chicago, IL

Daniel J. Calac, MD
Indian Health Council, Inc
San Diego, CA

Maria Elena Martinez, PhD
UC San Diego
La Jolla, CA

George Sledge, Jr, MD
Stanford University
Stanford, CA

Lisa C. Richardson, MD, MPH
CDC Division of Cancer Prevention and Control
Decatur, GA

Patient Advocates

Darcy Burbage, DNP, RN, AOCN
Newark, DE

Na'Diah Smith
Tigerlily Foundation Breast Cancer ANGEL Advocate

Aliya Whipple
Tigerlily Foundation Breast Cancer ANGEL Advocate

Keynote #2

Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Panel 2: Diversity in Clinical Trials – From Ideation to Implementation

COVID Update

Erica Stringer-Reasor, MD
UAB Medicine
Birmingham, AL

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Amelie Ramirez, DrPH
UT Health San Antonio
San Antonio, TX

Melissa Davis
New York University
New York, NY

Sophia George, PhD
University of Miami Cancer Center
Miami, FL

Lori L. Wilson, MD
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Patient Advocates

Thelma Brown
University of Alabama at Birmingham
Patient Research Advocate
Birmingham, AL

Ashley Dedmon, MPH, CHES
Tigerlily Foundation Breast Cancer ANGEL Advocate
Iowa Colony, TN

Ysabel Duron
The Latino Cancer Institute
San Jose, CA

4:00 PM - 5:00 PM CT

Susan G. Komen® Brinker Awards for Scientific Distinction Lectures – Hall 3

Brinker Award for Scientific Distinction in Basic Science

Carlos Caldas, MD, FMedSci
University of Cambridge
Cambridge, United Kingdom

Brinker Award for Scientific Distinction in Clinical Research

Judy Garber, MD, MPH
Harvard Medical School
Boston, MA

5:00 PM - 7:00 PM CT

EDUCATIONAL SESSIONS

Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees with a better understanding of the background leading up to talks they will hear in the succeeding days, and some of the techniques that will be used. These presentations should also provide researchers with ideas and techniques to be considered for their own studies.

Triple Positive Breast Cancer – Stars at Night Ballroom 1&2

Moderator: Jenny C. Chang, MD, MB BCHir
Houston Methodist Hospital
Houston, TX

The ideal partner to HER2 directed therapies

Sara A. Hurvitz, MD
UCLA
Los Angeles, CA

ER/HER2+ cross talk

Charles M. Perou, PhD
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Escalating and de-escalation - titrating the right regimen in early stage HER2 positive

Nadia Harbeck, MD, PhD
University of Munich
Munich, Germany

Artificial Intelligence: Beyond the Soundbites supported by the Lobular Breast Cancer Alliance – **Stars at Night Ballroom 3&4**

Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Everything you always wanted to know about AI but were afraid to ask

Regina Barzilay, PhD
MIT
Cambridge, MA

Artificial intelligence: Guiding the pathologists' eyes

Thomas J. Fuchs
Memorial Sloan Kettering Cancer Center
New York, NY

Artificial intelligence in radiology

Gopal Vijayaraghavan, MD, MPH
University of Massachusetts Medical School
Worcester, MA

Refining Heredity Risk – Hall 4B

Moderator: Olufunmilayo (Funmi) Olopade, MD, FACP
University of Chicago
Chicago, IL

Reclassifying VUS: New techniques can solve the puzzle once and for all

Sean V. Tavtigian, PhD
Huntsman Cancer Institute at the University of Utah
Salt Lake City, UT

Clinical management of moderate penetrance genes

Allison W. Kurian, MBBS, MD, MSc
Stanford University School of Medicine
Palo Alto, CA

Polygenic risk score: Should clinicians use it

Montserrat García-Closas, MD, DrPH
National Cancer Institute
Rockville, MD

Panel Discussion



Evidence Based Integrative Therapies - During and Beyond Treatment – Hall 4A

Moderator: Dawn L. Hershman, MD, MS

Columbia University

Herbert Irving Comprehensive Cancer Center

New York, NY

Acupuncture

Ting Bao, MD, DABMA, MS

Memorial Sloan Kettering Cancer Center

New York, NY

Hypnosis and mindfulness

David Spiegel, MD

Stanford University

Stanford, CA

Complementary treatments

Donald Abrams, MD

University of California, San Francisco

San Francisco, CA

What does diet and exercise change really do for you

Nicole Simone, MD

Thomas Jefferson University

Philadelphia, PA

Panel Discussion

7:00 PM - 8:45 PM CT

OPEN SATELLITE EVENTS - Live Symposia will be held at the San Antonio Marriott Rivercenter.

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer (Part 1 of a 3-Part CME Series) presented by Research to Practice

Register for this complimentary live symposia or virtual event:

<http://www.researchtopractice.com/Meetings/SA2021>

Optimizing Immunotherapy in Triple Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Based Efficacy Monitoring

presented by Oncocyte

WEDNESDAY, DECEMBER 8, 2021

7:00 AM - 8:30 AM CT
POSTER SESSION 1 – Hall 1

7:00 AM - 8:30 AM CT
SPOTLIGHT POSTER DISCUSSION SESSIONS

Spotlight Poster Discussion 1- Endocrine Resistance: Novel mechanisms and emerging new therapies – Stars at Night Ballroom 3&4

Chair: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

New mechanistic insights to ER biology and endocrine therapies

Luca Magnani, PhD
Imperial College London
London, United Kingdom

Transcriptional reprogramming, ESR1 mutations, and novel targets and treatment

Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

Spotlight Poster Discussion 2 - Insights to CDK4/6i resistance: Novel models and clinical/translational genomics Hall 4A

Chair: Richard Finn, MD
Geffen School of Medicine at UCLA
Los Angeles, CA

Are we closer to understanding why CDK 4/6 inhibitors stop working and what to do about it

Shom Goel, MD, PhD
Peter MacCallum Cancer Centre
Melbourne, Australia

Three CDK 4/6 inhibitors, a lot of biomarkers, what does it all mean moving forward?

Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Spotlight Poster Discussion 3 - Targets in Triple Negative Breast Cancer – Stars at Night Ballroom 1&2

Chair: Justin M. Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

Immunotherapy/genomic implications

Clinton Yam, MD
UT MD Anderson Cancer Center
Houston, TX

Combined inhibition of CDK4/6 and AKT (LAR subtype)

Jennifer Richer, PhD
University of Colorado
Denver, CO

8:30 AM - 11:15 AM CT

GENERAL SESSION 2 – Hall 3

Moderator: Olufunmilayo (Funmi) Olopade, MD, FACP
University of Chicago
Chicago, IL

8:30 AM CT

GS2-00 GS2-00 Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2- advanced breast cancer

Carey L, Solovieff N, André F, O'Shaughnessy J, Cameron DA, Janni W, Sonke GS, Yap Y-S, Yardley DA, Zarate JP, Taran T, Su F, Lteif A, Prat A. University of North Carolina, Chapel Hill, NC; Novartis Institutes for Biomedical Research, Cambridge, MA; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Texas Oncology-Baylor University Medical Center and The US Oncology Research Network, Dallas, TX; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom; Department of Gynecology, University of Ulm, Ulm, Germany; Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, Netherlands; National Cancer Center Singapore, Singapore, Singapore; Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain.

8:45 AM CT

GS2-01. Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer

O'Shaughnessy J, Stemmer SM, Burris HA, Yap Y-S, Sonke G, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga C, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, Hortobagyi GN. Texas Oncology-Baylor University Medical Center and The US Oncology Research Network, Dallas, TX; Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Sarah Cannon Research Institute, Nashville, TN; Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Medical Oncology, Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, FL; Department of Medical Oncology, Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain, France; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Gynecology, University of Ulm, Ulm, Germany; Department of Surgery, Oncology and Gastroenterology and Division of Medical Oncology; University of Padua and Istituto Oncologico Veneto, IRCCS, Padua, Italy; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Harold C. Simmons Comprehensive Cancer Center, UT

Southwestern Medical Center, Dallas, TX; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

9:00 AM CT

GS2-02. Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial

Bardia A, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier M-A, Sohn JH, Vuylsteke P, Harnden KK, Khong H, Kocsis J, Dalenc F, Kaklamani , Dillon P, Babu S, Waters S, Deleu I, García-Sáenz J, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortes J, Liu S, Laurent D, Conlan MG, Bidard F-C. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute, Leuven, Belgium; Centro Médico Austra, Buenos Aires, Argentina; University Hospitals Seidman Cancer Center- Case Western Reserve University, Cleveland, OH; Centre Hospitalier de l'Ardenne - Site de Libramont, Libramont-Chevigny, Belgium; Centre Jean Perrin, Clermont-Ferrand, France; Yonsei Cancer Center, Yonsei University Health System -Medical Oncology, Seoul, Republic of Korea; CHU UCL Namur – Site Sainte-Elisabeth, Namur, Belgium; Inova Schar Cancer Institute, Fairfax, VA; Moffit Cancer Center & Research Institute, Tampa, FL; Bács-Kiskun Megyei Kórház, Kecskemét, Hungary; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; University of Texas Health Sciences Center, Houston, TX; University of Virginia Cancer Center, Charlottesville, VA; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; Velindre Cancer Centre, Cardiff, United Kingdom; AZ Nikolaas, Sint-Niklaas, Belgium; Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; Ospedale San Gerardo-ASST Monza, Monza, Italy; University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA; Institut Jules Bordet – Université Libre de Bruxelles, Brussels, Belgium; International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain; Cytel, Waltham, MA; Berlin Chemie AG/Menarini Ricerche S.p.A, Berlin, Germany; Radius Health, Inc., Boston, MA; Institut Curie, Paris and Saint Cloud, France.

9:15 AM CT

GS2-03. Discussant

David W. Cescon, MD, PhD
Princess Margaret Cancer Centre
Toronto, Canada

9:30 AM CST

GS2-04. Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials

Bradley R, Braybrooke J, Gray R, Hills RK, Lui Z, Pan H, Peto R, Bergh J, Swain SM, Francis P, Gnant M, Perrone F, Regan MM. University of Oxford, Oxford, United Kingdom; Karolinska University Hospital, Solna, Sweden; Georgetown University Medical Center, Washington, WA; University of Melbourne, Melbourne, Australia; Medical University of Vienna, Vienna, Austria; National Cancer Institute of Naples, Naples, Italy; Dana-Farber Cancer Institute, Boston, MA.

9:45 AM CST

GS2-05. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials

Regan MM, Walley BA, Fleming GF, Francis PA, Colleoni MA, Láng I, Gómez HL, Tondini CA, Burstein HJ, Goetz MP, Ciruelos EM, Stearns VJ, Bonnefoi HR, Martino S, Geyer, Jr, CE, Chini C, Minisini AM, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Goldhirsch A, Gelber RD, Pagani O. SOFT and TEXT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Groups, Bern, Switzerland.

10:00 AM CST

GS2-06. Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials

Braybrooke J, Bradley R, Gray R, Hills R, Liu Z, Pan H, Peto R, Blum J, Chen X, Ejlersen B, Janni W, Nitz U, Slamon D, Toi M, Watanabe T, Swain S, Bergh J, on behalf of the Early Breast Cancer Trialists Collaborative Group. University of Oxford, Oxford, United Kingdom; Baylor University Medical Centre, Dallas, TX; Shanghai Jiao Tong University, Shanghai, China; University of Copenhagen, Copenhagen, Denmark; University of Ulm, Ulm, Germany; West German Study Group, Mönchengladbach, Germany; University of California Los Angeles, Los Angeles, CA; Kyoto University, Kyoto, Japan; Hamamatsu Oncology Centre, Hamamatsu, Japan; Georgetown University Medical Center, Washington, DC; Karolinska University Hospital, Stockholm, Sweden.

10:15 AM CST

GS2-07. Distant-disease free interval in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and her2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < or = 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG s1007 (RxPONDER)

Kalinsky KM, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LA, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierra J-Y, Bermejo B, Ramos-Vasquez M, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Pusztai L, Hortobagyi G. Emory University Winship Cancer Institute (SWOG), Atlanta, GA; SWOG Statistics and Data Management Center (SWOG), Seattle, WA; University of Washington School of Medicine/Seattle Cancer Care Alliance (SWOG), Seattle, WA; University of Texas MD Anderson Cancer Center (SWOG), Houston, TX; Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center (SWOG), Maywood, IL; Breast Oncology Program, Division of Hematology/Oncology, Department of Medicine, University of Michigan (SWOG), Ann Arbor, MI; Dana Farber Cancer Institute, Medical Oncology (Alliance for Clinical Trials in Oncology), Boston, MA; Mayo Clinic Jacksonville, Hematology/Oncology Division (Alliance for Clinical Trials in Oncology), Jacksonville, FL; Fox Chase Cancer Center (ECOG-ACRIN), Philadelphia, PA; British Columbia Cancer Agency, Medical Oncology (CCTG), Vancouver, BC, Canada; Juravinski Cancer Centre (CCTG), Hamilton, ON, Canada; Emory University Winship Cancer Institute (SWOG), University of Pittsburgh (NRG), PA; Hospital Clínico Virgen de la Victoria, UGCI Medical Oncology, IBIMA. GEICAM, Spanish Breast Cancer Group., Málaga, Spain; Institut Gustave Roussy (UNICANCER), Paris, France; Instituto de Investigación Sanitaria Gregorio Marañón,

Department of Medical Oncology; Centro de Investigación Biomedica en Red de Oncología, CIBERONC-ISCIII, sM Spanish Breast Cancer Group (GEICAM), Madrid, Spain; Mater Misericordiae University Hospital, Department of Medical Oncology; University College Dublin (Cancer Trials Ireland), Dublin, Ireland; Hospital Virgen del Rocío. GEICAM, Spanish Breast Cancer Group., Sevilla, Spain; L'Hospitalet de Llobregat, Medical Oncology. GEICAM, Spanish Breast Cancer Group, Barcelona, Spain; Instituto Nacional De Cancerologia (INCan), Mexico City, Mexico; Institut Curie (UNICANCER), Saint Cloud, France; National Cancer Center-Korea (NCC-Korea), Goyang-si Gyeonggi-do, Republic of Korea; Institut Curie Paris (UNICANCER), Paris, France; Hospital Clinico Universitario de Valencia; Biomedical Research Institute INCLIVA; Centro de Investigación Biomedica en Red de Oncología, CIBERONC-ISCIII. GEICAM Spanish Breast Cancer Group, Valencia, Spain; Centro Oncológico de Galicia. GEICAM Spanish Breast Cancer Group, A Coruña, Spain; University of Ulsan College of Medicine, Ulsan Medical Center (Korean Cancer Study Group), Seoul, Republic of Korea; Centre Antoine Lacassagne, Medical Oncology (UNICANCER), Nice, France; Genomic Health/Exact Sciences, Redwood City, CA; University of Kansas Medical Center, Internal Medicine (SWOG), Kansas City, KS; Yale University (SWOG), New Haven, CT.

10:30 AM CT
GS2-08. Discussant

Anne Blaes, MD
University of Minnesota
Minneapolis, MN

10:45 AM CT
GS2-09. Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations

Kubler K, Nardone A, Anand S, Gorvich D, Droog M, Hermida-Prado F, Akshi T, Feit AS, Cohen G, Dackus G, Pun M, Kuang Y, Cha J, Miller M, Gibson WJ, Paweletz CP, Van Allen EM, van Leeuwen FE, Nederlof P, Hollema H, Nguyen Q-D, Mourits MJE, Leshchiner I, Stewart C, Matulonis UA, Zwart W, Maruvka YE, Getz G, Jeselsohn R. Broad Institute, Cambridge, MA; Dana Farber Cancer Institute, Boston, MA; Technion, Haifa, Israel; Netherlands Cancer Institute, Amsterdam, Netherlands; University of Groningen, Groningen, Netherlands.

11:00 AM CT
GS2-10. Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)

Barroso-Sousa R, Li T, Reddy S, Emens LA, Overmoyer B, Lange P, Dilullo MK, Attaya V, Kimmel J, Winer EP, Mittendorf EA, Tayob N, Tolaney SM. Hospital Sirio-Libanés, Brasília, Brazil; Dana-Farber Cancer Institute, Boston, MA; University of Texas Southwestern Medical Center, Houston, TX; University of Pittsburgh Medical Center, Pittsburgh, PA.

11:15 AM CT

Break

10:00 AM - 5:00 PM CT

EXHIBITS – Hall 2

11:30 AM - 12:00 PM CT
WILLIAM L. MCGUIRE MEMORIAL LECTURE – Hall 3
Heterogeneity of Breast Cancer Genomes: Going Beyond Therapy to Risk Assessment and Prevention

Olufunmilayo (Funmi) Olopade, MD, FASCO, FACP, OON, FAACR

University of Chicago Medicine
Chicago, IL

12:00 PM - 1:00 PM CT

CAREER DEVELOPMENT FORUM sponsored by Eisai, Inc. – Room 304

The Career Development Forum provides interactive informational interviews with experts on a variety of topics that are important for the career development of early-career scientists. The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2021 SABCS. In-person and virtual opportunities will be available for the Career Development Forum.

Attendance to the Virtual Career Development Forum will require pre-registration and will be limited to 60 participants. An invitation with a link to the pre-registration form will be sent to early-career scientists registered with a virtual registration ticket to the 2021 SABCS on Monday, November 22. The full program, including the participating mentors and list of breakout career topics, is available [HERE](#).

Attendance to the in-person Career Development Forum will be limited to 120 participants on a first-come, first-served basis and limited to 120 participants. Pre-registration is not required, but badges are will be scanned at door for registration. Boxed lunches will be provided. Participants may visit as many or few tables during the session as they like. Some tables topics will have a more clinical focus, while others will have a more laboratory research focus. The subthemes are denoted in parenthesis after the table topic name.

In- Person CDF Schedule

12:00 pm - 12:05 pm Introduction

12:05 pm - 1:00 pm Rotation through roundtables (at leisure)

Roundtable Topics

12:05 - 1:00 pm

1. Balancing Research and Clinical Practice (Clinical)

- a. Cynthia Ma, Washington University Siteman Cancer Center, St. Louis, MO
- b. Mentor to be announced
- c. Jerri Francoeur, Alamo Breast Cancer Foundation, San Antonio, TX

2. Becoming a Successful Clinicl Trialist (Clinical)

- a. Carey Anders, Duke Comprehensive Cancer Center, Durham, NC
- b. Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
- c. Advocate to be announced

3. Careers in Industry

- a. Oyewale Daejin Abidoye, Gilead Sciences Inc., Foster City, CA
- b. Kim L. Blackwell, Tempus Labs, Indianapolis, IN
- c. Amy C. Peterson, CytomX, South San Francisco, CA
- d. Stacey Tinianov, Advocate Collaborative



4. Careers in Translational Research (Clinical)

- a. Minetta C. Liu, Mayo Clinic College of Medicine and Science, Rochester, MN
- b. Rita Nanda, University of Chicago, Chicago, IL
- c. Janice Cowden, GRASP

5. Careers in Translational Research (Laboratory)

- a. Justin M. Balko, Vanderbilt University, Nashville, TN
- b. Mentor to be announced
- c. Advocate to be announced

6. Making the Transition from Fellowship to Faculty (Clinical)

- a. Dawn L. Hershman, Columbia University, New York, NY
- b. Erica Stringer-Reasor, University of Alabama at Birmingham, Birmingham, AL
- c. Advocate to be announced

7. Making the Transition from Fellowship to Faculty (Laboratory)

- a. Fabrice André, Institut Gustave Roussy, Villejuif, France
- b. Alana L. Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
- c. Abigail Johnson, Connect IV Legal Services, Inc.

8. Negotiating a Job Offer or Promotion

- a. Norah Lynn Henry, University of Michigan, Ann Arbor, MI
- b. Kevin Kalinsky, Emory Winship Cancer Center, Atlanta, GA
- c. Jamie LaScala, Patient Advocate Board Member Translational Center of Excellence in Breast Cancer, Penn Medicine, Philadelphia, PA

9. How to Get Involved In & Make Collaborative Research Work for You

- a. Angela M. DeMichele, University of Pennsylvania, Philadelphia, PA
- b. Jorge Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, NY
- c. Ginny Mason, Inflammatory Breast Cancer Research Foundation, West Lafayette, IN

10. Time Management to Optimize Productivity

- a. Shelley Hwang, Duke Comprehensive Cancer Center, Durham, NC
- b. Erika P. Hamilton, Sarah Cannon Research Institute, Nashville, TN
- c. Bárbara Segarra-Vázquez, University of Puerto Rico, San Juan, PR



**12:00 PM - 2:00 PM CT
SPECIAL SESSIONS**

Re-framing Leadership in Academic Breast Oncology post COVID-19 – Hall 4A

Co-Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Co-Moderator: Rebecca Dent, MD
MScNational Cancer Center Singapore
Singapore, Singapore

Co-Moderator: Lisa Carey, MD, ScM, FASCO
University of North Carolina at Chapel Hill
Chapel Hill, NC

Learning by leading- lessons learned

Clifford A. Hudis, MD, FACP, FASCO
American Society of Clinical Oncology
Alexandria, VA

Building a successful translational breast cancer research program

Matthew J. Ellis, MB, BChir, BSc., PhD, FRCP
Lester and Sue Smith Breast Center
Baylor College of Medicine
Houston, TX

Panel Members:

Lisa A. Carey, MD, ScM, FASCO
University of North Carolina at Chapel Hill
Chapel Hill, NC

Charles M. Perou, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

**Regulatory Insights to the 2021 Early Stage Breast Cancer Approvals –
Stars at Night Ballroom 3&4**

Moderator: Laleh Amiri Kordestani, MD
Food and Drug Administration
Silver Spring, MD

Christy Osgood, MD
Food and Drug Administration
Silver Spring, MD



Mirat Shah, MD
Food and Drug Administration
Silver Spring, MD

Melanie Royce, MD
Food and Drug Administration
Silver Spring, MD

Alberto Montero, MD
University Hospitals Seidman Cancer Center
Cleveland, OH

Health Equity in Translational Research Studies – Stars at Night Ballroom 1&2

Co-Moderator: Melissa L. Bondy, PhD
Stanford Medicine
Stanford, CA
and

Co-Moderator: Patty Spears
University of North Carolina at Chapel Hill
Chapel Hill, NC

Working with patient advocates to promote diversity in trial participation and biospecimen donation

Vernal Branch
UNC Chapel Hill Breast SPORE
Chapel Hill, NC

Increasing accrual of Latinos into clinical trials: A cancer center's perspective

Amelie Ramirez, DrPH
UT Health San Antonio
San Antonio, TX

Engaging racial and ethnic minority women in clinical trials and biospecimen donation: Keeping it simple, strategic, and sincere

Vanessa B. Sheppard, PhD
Virginia Commonwealth University
Richmond, VA

Integrating community networks in cancer research to increase diversity in clinical trials accrual

Lidia Schapira, MD, FASCO
Stanford University School of Medicine
Stanford, CA

Supporting and infusing health equity in translational research at the investigator and organizational level

Melissa Simon, MD, MPH
Northwestern University
Chicago, IL

Panel Discussion

2:00 PM - 3:00 PM CT

TRANSLATIONAL SCIENCE FORUM

ER Mutations and SERDS – Stars at Night Ballroom 3&4

Moderator: Fabrice André, MD, PhD
Institut Gustave Roussy
Villejuif, France

Next generation sequencing in ER targets

Donald P. McDonnell, PhD
Duke University School of Medicine
Durham, NC

ER+ word salad decoded: SERD, SERM, SERCA, CERAN, PROTAC

Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center
New York, NY

BASIC SCIENCE FORUM

Targeting Nuclear Steroid Receptors – Hall 4

Moderator: Carol Lange, PhD
University of Minnesota
Minneapolis, MN

A new perspective on androgen receptor action in estrogen receptor- α positive breast cancer

Wayne Tilley, PhD
The University of Adelaide
Adelaide, Australia

PR

Christy R. Hagan, PhD
University of Kansas Medical Center
Kansas City, KS

GR

Suzanne Conzen, MD
UT Southwestern Medical Center
Dallas, TX

CASE DISCUSSIONS – Stars at Night Ballroom 1&2

Clinical Case Discussion

Moderator: Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

Panel Members

Thelma Brown
Boon H. Chua, MBBS PhD FRANZCR
Hope S. Rugo, MD FASCO
Anne Vincent-Solomon, MD, PhD
Lee G. Wilke, MD

3:00 PM - 5:00 PM CT

EDUCATIONAL SESSIONS

Triple Negative Breast Cancer: Critical Update on Biology and Management –

Stars at Night Ballroom 1&2

Moderator: Rita Nanda, MD
University of Chicago
Chicago, IL

Genomic and transcriptomic landscape of TNBC

Zhi-Ming Shao, MD
Fudan University of Shanghai
Shanghai, China

Optimizing the management of early stage TNBC

Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Brigham and Women's Cancer Center
Boston, MA

Management of special subtypes of TNBC

Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

Emerging Adjuvant Therapies: What's Ready for Prime Time? – Stars at Night Ballroom 3&4

Moderator: Angela DeMichele, MSCE
University of Pennsylvania
Philadelphia, PA

Approving new therapies for early breast cancer

Suparna Wedam, MD
Food and Drug Administration
Silver Spring, MD

CDK4/6 for ER+

Ingrid A. Mayer, MD, MSCI
Vanderbilt-Ingram Cancer Center
Nashville, TN

IO vs Capecitabine for TNBC

Sherene Loi, MD, PhD
Peter MacCallum Cancer Centre
Melbourne, Australia

PARP for BRCA+ breast cancers

Andrew Tutt, MD
Institute of Cancer Research
London, United Kingdom

Fine Tuning Risk Assessment and Risk Reduction – Hall 4B

Moderator: Banu Arun, MD
UT MD Anderson Cancer Center
Houston, TX

Lifestyle: Exercise and diet

Neil M. Iyengar, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Emergent pharmacologic interventions for prevention: Non endocrine

treatments

Brandy Heckman-Stoddard, PhD, MPH
National Cancer Institute
Rockville, MD

Imaging/AI

Constance Lehman, MD, PhD
Massachusetts General Hospital
Boston, MA

Panel Discussion

Ashley A. Dedmon

SABCS with the Society of Surgical Oncology present
Local Therapy - Management of the Axilla – Hall 4A

Moderator: Hiram (Chip) Cody, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Axillary management in upfront surgery - staging, local control or both?

Stephanie Wong, MD, MPH
McGill University
Montreal, Canada

Refining axillary management after neoadjuvant chemotherapy - what does the evidence support

Eleftherios (Terry) Mamounas, MD, MPH, FACS
Orlando Health Cancer Institute
Orlando, FL

Can radiation replace ALND after + SLNB

Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Options for reducing risk for lymphedema when ALND/regional nodal XRT are needed

Hani Sbitany, MD
Mount Sinai
New York, NY

5:00 pm - 6:30 pm CT
POSTER SESSION 2 – Hall 1

5:00 pm - 6:30 pm CT
SPOTLIGHT POSTER DISCUSSIONS

Spotlight Poster Discussion 4 - Brain Metastases: Managing LMD / Targeting HER2 – Stars at Night Ballroom 3&4

Chair: Andrew Brenner, MD
UT Health San Antonio
San Antonio, TX

Patricia Steeg, PhD
National Cancer Institute
Bethesda, MD

Eudocia Lee, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Spotlight Poster Discussion 5 - Life after breast cancer: Cardiac health, fertility preservation, and returning to life – Stars at Night Ballroom 1&2

Chair: Kathryn Ruddy, MD, MPH
Mayo Clinic
Rochester, MN

Cardiotoxicity

Carmen Bergom, MD, PhD
Washington University School of Medicine
St. Louis, MO

Ovarian reserve and assisted reproduction

Maryam Lustberg, MD, MPH
Yale University School of Medicine
New Haven, CA

Employment changes, sedative hypnotic use, and risk of long-term chemotherapy toxicity

Tara Sanft, MD
Yale Cancer Center
New Haven, CT

Spotlight Poster Discussion 6 - Genomic and genetic analysis on metastases – Hall 4A

Chair: Christina Curtis, PhD, MSc
Stanford University
Stanford, CA

Christina Curtis, PhD MSc
Stanford University
Stanford, CA

Daniel Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH

7:00 PM - 9:00 PM CT

OPEN SATELLITE EVENT - San Antonio Marriott Rivercenter.

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer (Part 2 of a 3-Part CME Series) presented by Research to Practice

Register for this complimentary live symposia or virtual event:
<http://www.researchtopractice.com/Meetings/SA2021>

7:30 PM - 9:30 PM CT

OPEN SATELLITE EVENT - San Antonio Marriott Rivercenter.

Navigating the Evolving Treatment Landscape for ER-Positive Breast Cancer presented by Physicians' Education Resource

Register for this complimentary live symposia or virtual event:
HOME - Medical Crossfire®: Navigating the Evolving Treatment Landscape
for HR-Positive Breast Cancer (gotoper.com)

THURSDAY, DECEMBER 9, 2021

7:00 AM - 8:30 AM CT
POSTER SESSION 3 – Hall 1

7:00 AM - 8:30 AM CT
SPOTLIGHT POSTER DISCUSSION SESSIONS

Spotlight Poster Discussion 7 - Locoregional treatment: De-escalation in breast cancer – Stars at Night Ballroom 1&2

Chair: Wendy A. Woodward
UT MD Anderson Cancer Center
Houston, TX

Reducing and omitting radiotherapy for select breast cancers

Julie A. Bradley, MD
UF Health Proton Therapy Institute
Jacksonville, FL

Topics in surgical omission: Is less always more?

Alastair M. Thompson, BSc (Hons), MBChB, MD, FRCS (Ed)
Baylor College of Medicine
Houston, TX

Spotlight Poster Discussion 8 - HER2 Positive Breast Cancer – Stars at Night Ballroom 3&4

Chair: Ian E. Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Optimizing use of HER2 therapies in metastatic HER2+ breast cancer and other subtypes

Priyanka Sharma, MD
University of Kansas Cancer Center
Westwood, KS

HER2 kinase inhibitors: neoadjuvant approaches and mechanisms of resistance

Cristina Saura Manich, MD
Vall d'Hebron University Hospital
Barcelona, Spain

Novel therapies for HER2+ advanced breast cancer

Jo Chien, MD
University California San Francisco
San Francisco, CA

Spotlight Poster Discussion 9 - Evaluating emerging and established biomarkers – Hall 4A

Co-Chair: W. Fraser Symmans, MB ChB
UT MD Anderson Cancer Center
Houston, TX

Co-Chair: Dennis Sgroi, MD
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

8:45 AM - 11:15 AM CT

GENERAL SESSION 3 – HALL 3

Co-Moderator: Powel Brown, MD, PhD
University of Texas MD Anderson Cancer Center
Houston, TX
and

Angela DeMichele, MD MSCE
University of Pennsylvania
Philadelphia, PA

8:45 AM CT

GS3-01. Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer: Results of the randomized phase 3 study DESTINY-Breast03

Hurvitz S, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, Kim M-H, Tseng L-M, Petry V, Chung C-F, Iwata H, Hamilton E, Curigliano G, Xu B, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Cortés J. University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; National Cheng Kung University Hospital, Tainan, Taiwan; Seoul National University Hospital, Seoul, Republic of Korea; Samsung Medical Center, Seoul, Republic of Korea; Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda., Sao Paulo, Brazil; Severance Hospital, Yonsei University, Seoul, Republic of Korea; Taipei Veterans General Hospital, Taipei, Taiwan; Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, Sao Paulo, Brazil; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan; Aichi Cancer Center Hospital, Aichi, Japan; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; European Institute of Oncology, IRCCS, University of Milano, Milano, Italy; Chinese Academy of Medical Sciences Cancer Hospital, Beijing, China; Daichi Sankyo, Inc., Basking Ridge, NJ; AstraZeneca Pharmaceuticals, LP, Gaithersburg, MD; International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain.

9:00 AM CT

GS3-02. Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer

Xu B, Yan M, Ma F, Hu X, Feng J, Ouyang Q, Tong Z, Li H, Zhang Q, Sun T, Wang X, Yin

Y, Cheng Y, Li W, Zhu X, Chen C, Jianjun Zou J. Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China; The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China; National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Fudan University Cancer Hospital, Shanghai, China; Jiangsu Cancer Hospital, Nanjing, China; Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China; Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Beijing Cancer Hospital, Beijing, China; Harbin Medical University Cancer Hospital, Harbin, China; Liaoning Cancer Hospital & Institute, Shenyang, China; Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, China; The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; Jilin Cancer Hospital, Changchun, China; The First Bethune Hospital of Jilin University, Changchun, China; Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China.

9:15 AM CT
GS3-03. Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities

Ferraro E, Smith A, Safonov A, Tallon De Lara P, Bernado' C, Arenas Lahuerta EJ, Arribas J, Solit D, Reis-Filho JS, Rosen N, Norton L, Modi S, Robson ME, Dang CT, Curigliano G, Chandarlapaty S, Razavi P. Memorial Sloan Kettering Cancer Center, New York City, NY; Vall D'Hebron Institute of Oncology, Barcelona, Spain; University of Milan, European Institute of Oncology, Milan, Italy.

9:30 AM CT
GS3-04. Discussant

Ciara O'Sullivan, MB, BCh
Mayo Clinic
Rochester, MN

9:45 AM CT
GS3-05. Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

Bidard F-C, Hardy-Bessard A-C, Bachelot T, Pierga J-Y, Canon J-L, Clatot F, Andre F, De La Motte Rouge T, Pistilli B, Dalenc F, Dohollou N, Arsene O, Petit T, Riedl C, Morvan F, Marti A, Lachaier E, Achille M, Gozy M, Escande A, Mille D, Trouboul F, Arnould L, Bieche I, Pradines A, Lemonnier J, Berger F, Delalogue S. Institut Curie, Paris, France; CARIO - Centre Armoricaire Radiothérapie Imagerie Médicale et Oncologie, Plérin, France; Centre Léon Bérard, Lyon, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Centre Henri Becquerel, Rouen, France; Gustave Roussy, Villejuif, France; Centre Eugène Marquis, Rennes, France; Institut Claudius Régaud, Toulouse, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Centre Hospitalier de Blois, Blois, France; Centre Paul Strauss, Strasbourg, France; Centre Hospitalier Mont de Marsan, Mont de Marsan, France; Centre Hospitalier René Dubos, Cergy-Pontoise, France; Centre Hospitalier d'Auxerre, Auxerre, France; CHU d'Amiens, Amiens, France; Clinique de l'Orangerie, Strasbourg, France; Clinique de l'Europe, Amiens, France; Clinique Sainte Anne, Strasbourg, France; Medipole de Savoie, Challes les eaux, France; Centre Hospitalier Bretagne Atlantique, Vannes, France; Centre Georges François Leclerc, Dijon, France; Unicancer, Paris, France.

10:00 AM CT
GS3-06. Primary results of the cTRAK TN trial: A clinical trial utilising ctDNA

mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer

Turner N, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Hall P, Harper-Wynne C, Hickish T, Kernaghan S, Macpherson I, Okines A, Palmieri C, Perry S, Randle K, Snowdon C, Stobart H, Wardley A, Wheatley D, Waters S, Winter M, Bliss J. The Institute of Cancer Research, London, United Kingdom; The Institute of Cancer Research & The Royal Marsden Hospital, London, United Kingdom; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom; University of Edinburgh, Edinburgh, United Kingdom; Maidstone Hospital; Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom; Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Clatterbridge Cancer Centre NHS Trust, Liverpool, United Kingdom; Independent Cancer Patients' Voice, London, United Kingdom; Outreach Research & Innovation Group Ltd and AstraZeneca, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Velindre Cancer Centre; Velindre University NHS Trust, Cardiff, United Kingdom; Weston Park Hospital; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

10:15 AM CT

GS3-07. Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioTalee trial

Bianchini G, Malorni L, Arpino G, Zambelli A, Puglisi F, Del Mastro L, Colleoni M, Montemurro F, Bianchi G, Paris I, Allegrini G, Cazzaniga ME, Orditura M, Zamagni C, Tamberi S, Castelletti D, Benelli M, Callari M, Santoro A, De Laurentiis M. Department of Oncology, Ospedale San Raffaele, Milano, Italy; Department of Oncology and Translational Research Unit "Sandro Pitigliani", Ospedale di Prato, Azienda USL Toscana Centro, Prato, Italy; Department of Medical Clinics and Surgery, Università Federico II, Napoli, Italy; U.S.C. Oncologia, Presidio Ospedaliero Papa Giovanni XXIII, Bergamo, Italy; S.O.C. Oncologia Medica e Prevenzione Oncologica, IRCCS, Centro di Riferimento Oncologico, Aviano, Italy; U.O.S.D. Breast Unit, I.R.C.C.S. Ospedale Policlinico San Martino, Genoa, Italy; Senologia Medica, IEO, Istituto Europeo di Oncologia, IRCCS., Milano, Italy; Istituto di Candiolo, FPO, IRCCS, Candiolo., Torino, Italy; SC Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy; Department of Woman and Child Sciences, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy; Phase 1 Research Unit & Oncology Unit, Azienda Socio Sanitaria Territoriale Monza & Milano Bicocca School of Medicine and Surgery, Monza, Italy; U.O.C. Oncologia Medica e Ematologia, A.O.U. Università Degli Studi L. Vanvitelli, Napoli, Italy; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; U.O. Oncologia, P.O. Ospedale degli Infermi – AUSL, Ravenna, Italy; Oncology, Novartis Farma SpA, Origgio, Italy; Department of Oncology and Bioinformatics Unit, Ospedale di Prato, Azienda USL Toscana Centro, Prato, Italy; CRUK Cambridge Institute, University of Cambridge Li Ka Shing Centre, Cambridge, United Kingdom; IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy.

10:30 AM CT

GS3-08. Discussant

Minetta C. Liu, MD

Mayo Clinic
Rochester, MN

10:45 AM CT

GS3-09. Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer

Sudhan DR, Chatterjee S, Kim J, Wang Y, Kandagatla V, Ye D, Lin C-C, Gomez Tejada Zanudo J, Jain E, Marin A, Servetto A, Lee K-m, Povedano JM, McFadden D, Barrett A, Wagle N, Hanker AB, Arteaga CL. UT Southwestern Medical Center, Dallas, TX; Dana Farber Cancer Institute, Boston, MA; TEMPUS, Chicago, IL.

11:00 AM CT

GS3-10. Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Coombes C, Howell SJ, Krebs MG, Lord S, Kenny LM, Bahl A, Clack G, Ainscow E, Dickinson PA, Fostea R, Mansi J, Palmieri C, Bertelli G, Jeselsohn R, Mitri Z, Gradishar WJ, Sardesai S, O'Shaughnessy J, Ward P, Chalasani P, Lehnert M, Ali S, McIntosh S. Imperial College, London, United Kingdom; The University of Manchester, Manchester, United Kingdom; The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Carrick Therapeutics, Dublin, Ireland; SEDA Pharmaceutical Development Services, Stockport, United Kingdom; HCA Healthcare, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; University of Liverpool, Liverpool, United Kingdom; Brighton and Sussex University Hospital, Brighton, United Kingdom; Dana Faber Cancer Institute, Boston, MA; Oregon Health & Science University, Portland, OR; North Western University, Chicago, IL; The Ohio State University, Columbus, OH; The US Oncology Network, Dallas, TX; The University of Arizona, Tucson, AZ. 11:15 am CT

11:15 AM CT

BREAK

10:00 AM - 5:00 PM CT

EXHIBITS – Hall 2

11:30 AM - 12:30 PM CT

DEBATE – Hall 3

RxPONDER: Was it all OFS?

Chair: Harold Burstein MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Pro

Michael Gnant, MD
Medical University of Vienna
Vienna, Austria

Con

Sibylle Loibl, Dr Med
GBG Forschungs GMBH
Hessen, Germany

12:30 PM - 1:00 PM CT

AACR Distinguished Lectureship in Breast Cancer Research – Hall 3

Helen Piwnica-Worms, PhD
MD Anderson Cancer Center
Houston, TX

1:30 PM - 2:00 PM CT

PLENARY LECTURE 1 – HALL 3

Genomic Profiling in Early Stage ER Positive Breast Cancers/Precision Medicine

Mitchell Dowsett, PhD
Royal Marsden Hospital
London, United Kingdom

2:00 PM - 3:00 PM CT

TRANSLATIONAL SCIENCE FORUM

HER2 Heterogeneity – Hall 4A

Matthew J. Ellis, MB, BChir, BSc., PhD, FRCP
Baylor College of Medicine
Houston, TX

Basic

Kim RM Blenman, PhD, MS
Yale Cancer Center
Yale University
New Haven, CT

Heterogeneity in treatment outcomes for HER2+ breast cancer – Clinical management strategies

Sara M. Tolaney, MD, MPH
Dana Farber Cancer Institute
Boston, MA

Molecular heterogeneity in HER2+ breast cancer – can outcomes be predicted?

Aleix Prat, MD, PhD
Hospital Clinic Barcelona
Barcelona, Spain

CLINICAL SCIENCE FORUM – Stars at Night Ballroom 3&4

The Promise and Reality of Oligometastatic Ablation for Breast Cancer

Moderator: Steven J. Chmura, MD, PhD
University of Chicago
Chicago, IL

The Promise and Reality of Oligometastatic Ablation for Breast Cancer

Moderator: Steven J. Chmura, MD, PhD
University of Chicago
Chicago, IL

Oligometastatic disease: Definitions and practice patterns

Yolande Lievens, MD, PhD
UZ Gent
Ghent, Belgium

OMD data and gaps in breast cancer

David Palma, MD, PhD
London Health Sciences Center
Ontario, Canada

MOLECULAR TUMOR BOARD – Stars at Night Ballroom 1&2

Moderator: Ben Ho Park, MD, PhD
Vanderbilt University Medical Center
Nashville, TN

Panel Members:

Fabrice André, MD, PhD
Mark Burkard, MD, PhD
Sarat Chandarlapaty, MD, PhD
Susan Domchek, MD
Diana Mandelker, MD, PhD
Bob Riter, MHSA
Aditya Bardia, MD, MPH

3:00 PM - 5:00 PM CT

EDUCATIONAL SESSIONS

Local Therapy of the Primary and Beyond in Patients with Advanced Disease – Hall 4A

Moderator: Rajendra A. Badwe, MBBS, MS
Tata Memorial Centre
Mumbai, India

Local therapy of the primary tumor

Seema Khan, MD
Northwestern University
Chicago, IL

Special indications where local therapy should be considered

Anthony Lucci, MD
UT MD Anderson Cancer Center
Houston, TX

Oligo-progressive disease. Treating locally more than systemically

Amy Xu, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Clinical Updates on Immunotherapy – Hall 3

Moderator: Peter Schmid, MD, PhD
Bart's Cancer Institute Queen Mary University of London
London, United Kingdom

Immunotherapy in the metastatic setting - chemo backbone and biomarker

Rebecca Dent, MD
National Cancer Center
Singapore

Immune therapy in the (neo) adjuvant setting

Heather L. McArthur, MD, MPH
UT Southwestern
Dallas, TX

IO beyond TNBC

Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milan, Italy

Anti-cancer Immune Response – Hall 4B

Moderator: Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

Understanding the anti-cancer immune response: Innate and adaptive responses to cancer cells

Laurence Zitvogel, MD, PhD
Institut Gustave Roussy
Villejuif, France

Macro and micro: Macrophage and microbiome diversity in the breast cancer microenvironment

Jennifer L. Guerriero, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Optimizing immunotherapy efficacy in the clinic through biomarkers: Advances in single cell and spatial histology analyse

Marleen Kok, MD, PhD
The Netherlands Cancer Institute
Amsterdam, Netherland

The Fluid Landscape of Liquid Biopsy – Stars at Night Ballroom 3&4

Nicholas Turner, PhD, FRCF
The Royal Marsden Hospital Institute of Cancer Research
London, United Kingdom

Monitoring of advanced breast cancer with liquid biopsies

François-Clément Bidard, MD, PhD
Institut Curie
Paris Saclay University
Paris, France

Single cell analysis of circulating tumor cells

Shyamala Maheswaran, PhD
Massachusetts General Hospital
Boston, MA

Challenges in early detection - screening and MRD

Pedram Razavi, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Targeting the “Un-druggable” – Stars at Night Ballroom 1&2

Moderator: Funda Meric-Bernstam, MD
UT MD Anderson Cancer Center
Houston, TX



Targeting EZH2 functions

Celina G. Kleer, MD
University of Michigan Medical School
Ann Arbor, MI

RNA metabolism and splicing

Trey Westbrook, PhD
Baylor College of Medicine
Houston, TX

Novel epigenomic targets in TNBC

David W. Cescon, MD, PhD
Princess Margaret Cancer Centre
Toronto, Canada

5:00 PM - 6:30 PM CT

POSTER SESSION 4 – HALL 1

Spotlight Poster Discussion 10 - Novel immunotherapy approaches – Stars at Night Ballroom 1&2

Chair: Kevin Kalinsky, MD, MS
Winship Cancer Institute
Emory University
Atlanta, GA

Rebecca A. Shatsky, MD
UC San Diego Health
San Diego, CA

David B. Page, MD
Providence Cancer Institute
Portland, OR

Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Spotlight Poster Discussion 11 - The future is now: Innovation in pathology and radiology – Hall 4A

Co-Chair: Kalliopi P. Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Co-Chair: Sughra Raza, MD
University of Massachusetts Medical School
Worcester, MA

Innovation in Pathology



Lee A. Cooper, PhD
Northwestern Medicine
Feinberg School of Medicine
Chicago, IL

Innovation in Radiology

Linda Moy, MD
NYU Langone
New York, NY

7:00 PM - 8:45 PM CT

OPEN SATELLITE EVENT – San Antonio Marriott Rivercenter

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Triple-Negative Breast Cancer (Part 3 of a 3-Part CME Series) presented by Research to Practice

Register for this complimentary live symposia or virtual event:
<http://www.researchtopractice.com/Meetings/SA2021>

Candid Conversations & Clinical Consults: Personalizing Treatment Decisions in HER2-Altered Breast Cancer - Strategies for Improving Equity and Patient Outcomes Through Individualized Targeted Therapy Selection, Team-Based Care, and Shared Decision-Making presented by PVI, PeerView Institute for Medical Research

FRIDAY, DECEMBER 10, 2021

7:00 AM - 8:30 AM CT
POSTER SESSION 5 – Hall 1

7:00 AM - 8:30 AM CT
SPOTLIGHT POSTER DISCUSSION SESSIONS

Spotlight Poster Discussion 13 - Novel Therapeutic Approaches in HER2 Negative Breast Cancer – Stars at Night Ballroom 1&2

Chair: Sara M. Tolaney, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Going beyond just endocrine therapy: The path ahead

Mafalda Oliveira, MD, PhD
Vall d'Hebron Institute of Oncology
Barcelona, Spain

Novel strategies for endocrine therapy: Can we do better?

Heather A. Parsons, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Spotlight Poster Discussion 14 - Clinical translational updates in invasive lobular carcinoma – Stars at Night Ballroom 3&4

Rachel C. Jankowitz, MD
Penn Medicine
Philadelphia, PA

Christine Desmedt, PhD
Katholieke Universiteit Leuven
Leuven, Belgium

Spotlight Poster Discussion 15 - Defining molecular markers of endocrine resistance in clinic – Hall 4A

Chair: Lajos Pusztai, MD, DPhil
Yale University School of Medicine
New Haven, CT

Komal Jhaveri, MD FACP
Memorial Sloan Kettering Cancer Center
New York, NY

Reva Basho, MD
Cedars-Sinai Cancer
Los Angeles, CA

8:45 AM - 11:15 AM CT
GENERAL SESSION 4 – Hall 3

Moderator: Tari King, MD
Dana-Farber/Brigham and Women's Cancer Center
Boston, MA

8:45 AM CT

GS4-01. Impact of race and ethnicity on incidence and severity of breast cancer related lymphedema after axillary lymph node dissection: Results of a prospective screening study

Barrio AV, Montagna G, Sevilimedu V, Gomez EA, Mehrara B, Morrow M. Memorial Sloan Kettering Cancer Center, New York, NY.

9:00 AM CT

GS4-02. Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial

Kyalwazi B, Yau C, Olopade O, A, Chien J, Wallace A, Forero-Torres A, Puzstai L, Ellis E, Albain K, Blaes A, Haley B, Boughey J, Elias A, Clark A, Isaacs C, Nanda R, Han H, Yung R, Tripathy D, Edmiston K, Viscusi R, Northfelt D, Khan Q, Sanil A, Berry S, Asare S, Wilson A, Hirst G, Hylton N, Melisko M, Perlmutter J, Rugo H, Symmans F, van 't Veer L, Berry D, Esserman L. University of Chicago Pritzker School of Medicine, Chicago, IL; University of California San Francisco, San Francisco, CA; University of Chicago, Chicago, IL; University of California San Diego, San Diego, CA; University of Alabama at Birmingham, Birmingham, AL; University of Texas MD Anderson Cancer Center, Houston, TX; Swedish Cancer Institute, Seattle, WA; Loyola University Chicago Stritch School of Medicine, Chicago, IL; University of Minnesota, Minneapolis, MN; University of Texas Southwestern, Dallas, TX; Mayo Clinic Rochester, Rochester, MN; University of Colorado, Denver, CO; University of Pennsylvania, Philadelphia, PA; Georgetown, Washington, DC; Moffitt Cancer Center, Tampa, FL; University of Washington, Seattle, WA; University of Southern California, Los Angeles, CA; Inova Health System, Falls Church, VA; University of Arizona, Phoenix, AZ; Mayo Clinic Scottsdale, Scottsdale, AZ; University of Kansas, Kansas City, KS; Berry Consultants, LLC, Austin, TX; Quantum Leap Healthcare Collaborative, San Francisco, CA; Gemini Group, Ann Harbor, MI.

9:15 AM CT

GS4-03. Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): Persistent impact of axillary surgery on arm and breast symptoms in early breast cancer

Gerber B, Stachs A, Veselinovic K, Polata S, Müller T, Kühn T, Heil J, Ataseven B, Reitsamer R, Hildebrandt G, Knauer M, Golatta M, Stefek A, Zahn D-M, Thill M, Nekljudova V, Krug D, Seither F, Loibl S, Reimer T. Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany; Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany; Breast Center, Evangelisches Waldkrankenhaus Spandau, Berlin, Germany; Women's Hospital, Klinikum Hanau GmbH, Hanau, Germany; Women's Hospital, Klinikum Esslingen, Esslingen, Germany; Department of Obstetrics and Gynecology, Universitätsklinikum Heidelberg, Heidelberg, Germany; Kliniken Essen-Mitte, Essen, Germany; Breast Center, Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft, Salzburg, Austria; Department of Radiotherapy, University of Rostock, Rostock, Germany; Brustzentrum Ost, St. Gallen, Switzerland; Department of Obstetrics and Gynecology, Universitätsklinikum Heidelberg, Heidelberg, Germany; Women's Hospital, Johanniter-Krankenhaus Stendal, Stendal, Germany; Breast Center, SRH Waldklinikum Gera, Gera, Germany; Breast Center, AGAPLESION Markus Krankenhaus, Frankfurt, Germany; German Breast Group, Neu-Isenburg, Germany; Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

9:30 AM CT

GS4-04. Discussant

Lisa A. Newman, MD, MPH
New York-Presbyterian/Weill Cornell Medical Center
New York, NY

9:45 AM CT

GS4-05. Preservation of axillary lymph nodes compared to complete dissection in T1-T2 breast cancer patients presenting 1-2 metastatic sentinel lymph nodes. A multicenter randomized clinical trial. Sinodur One

Gentile D, Gatzemeier W, Barbieri E, Sagona A, Bottini A, Errico V, Testori A, Scorsetti M, Canavese G, Tinterri C. Humanitas Research Hospital, Milano, Italy.

10:00 AM CT

GS4-06 Estimation of breast cancer over diagnosis in a US breast screening cohort

Ryser MD, Lange J, Inoue L, O'Meara ES, Gard C, Miglioretti DL, Bulliard J-L, Brouwer AF, Hwang ES, Etzioni RB. Duke University, Durham, NC; Oregon Health & Science University, Portland, OR; University of Washington, Seattle, WA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; New Mexico State University, Las Cruces, NM; University of California, Davis, Davis, CA; University of Lausanne, Lausanne, Switzerland; University of Michigan, Ann Arbor, MI; Fred Hutchinson Cancer Research Center, Seattle, WA.

10:15 AM CT

GS4-07. The Breast PreCancer Atlas DCIS genomic signatures define biology and correlate with clinical outcomes: An analysis of TBCRC 038 and RAHBT cohorts

Strand SH, Rivero-Gutiérrez B, Houlihan KE, Seoane JA, King LM, Risom T, Simpson L, Vennam S, Khan A, Hardman T, Harmon BE, Couch FJ, Gallagher K, Kilgore M, Wei S, DeMichele A, King T, McAuliffe PF, Nangia J, Lee J, Tseng J, Storniolo AM, Thompson A, Gupta G, Burns R, Veis DJ, DeSchryver K, Zhu C, Matusiak M, Wang J, Zhu SX, Tappenden J, Yi Ding D, Zhang D, Luo J, Jiang S, Varma S, Straub C, Srivastava S, Curtis C, Tibshirani R, Angelo RM, Hall A, Owzar K, Polyak K, Maley C, Marks JR, Colditz GA, Hwang ES, West RB. Stanford, Stanford, CA; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Duke, Durham, NC; Montefiore, Bronx, NY; Mayo Clinic, Rochester, MN; University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Washington, Seattle, WA; University of Alabama at Birmingham, Birmingham, AL; University of Pennsylvania, Philadelphia, PA; Dana-Farber Cancer Institute, Boston, MA; University of Pittsburgh, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; MD Anderson Cancer Center, Houston, TX; University of Chicago, Chicago, IL; Indiana University, Indianapolis, IN; The EMMES Corporation, Rockville, MD; Washington University, St. Louis, MO; ASU, Tempe, AZ.

10:30 AM CT

GS4-08. Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance

Safonov A, Bandlamudi C, Tallón de Lara P, Ferraro E, Derakhshan F, Will M, Donoghue M, Selenica P, Drago J, Rosen E, dos Anjos C, Walsh E, Comen EA, Ahmed M, Acevedo B, Zehir A, Berger MF, Solit D, Norton L, Shen R, Stadler Z, Powell S, Reis-Filho JS, Chandralapaty S, Robson M, Razavi P. Memorial Sloan Kettering Cancer Center, New York, NY; University, St. Louis, MO; ASU, Tempe, AZ.

10:45 AM CT

GS4-09. Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer

Ganz PA, Bandos H, Spanic T, Friedman S, Müller V, Kümmel S, Delalogue S, Brain E, Toi M, Yamauchi H, de Dueñas E-M, Armstrong A, Im S-A, Song C, Zheng H, Sarosiek T, Sharma P, Rossi G, Rastogi P, Fielding A, Gelber RD, Campbell C, Garber JE, Geyer Jr CE, Tutt ANJ, On behalf of the OlympiA Trial Steering Committee and Investigators. NSABP/ NRG Oncology, and UCLA Jonsson Comprehensive Cancer Center, and UCLA Fielding School of Public Health, Los Angeles, PA; NSABP/NRG Oncology, and The University of Pittsburgh, Pgh, PA; Europa Donna, The European Breast Cancer Coalition, Milan, Italy; Facing Our Risk of Cancer Empowered (FORCE), Tampa, FL; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Charité – Universitätsmedizin Berlin, Department of Gynecology with Breast Center Breast Unit, Kliniken Essen-Mitte, Berlin, Germany; UNICANCER Breast Group (UCBG), Institut Gustave Roussy, Villejuif, France; Institut Curie, Saint-Cloud, France; Japan Breast Research Group (JBCRG), and Kyoto University Hospital, Kyoto, Japan; Japan Breast Research Group (JBCRG), and St. Luke's International Hospital, Tokyo, Japan; GEICAM Spanish Breast Cancer Group, and The Consorcio Hospitalario Provincial de Castellón, Castellón, Spain; National Cancer Research Institute - Breast Cancer Clinical Studies Group (NCRI-BCSG), The Christie NHS Foundation Trust, and the University of Manchester, Manchester, United Kingdom; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Fujian Medical University Union Hospital, Fujian, China; Cancer Center, West China Hospital, Sichuan University, Chengdu, China; LUXMED Onkologia, Warsaw, Poland; University of Kansas Medical Center, Westwood, KS; Breast International Group (BIG), Brussels, Belgium; NSABP/NRG Oncology, and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, and Magee-Womens Hospital, Pittsburgh, PA; AstraZeneca, Gaithersburg, MD; Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, MA; Frontier Science (Scotland) Ltd, Kinross, United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, and Alliance for Clinical Trials in Oncology, Boston, MA; NRG Oncology, and Houston Methodist Cancer Center, Houston, TX; Breast International Group (BIG), and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer and The Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London, London, United Kingdom.

11:00 AM CT

GS4-10. Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial

Jhaveri K, Park H, Waisman J, Goldman JW, Guerrero-Zotano A, Boni V, Haley B, Mayer IA, Brufsky A, Yang ES, García-Sáenz JA, Bidard F-C, Crown J, Zhang B, Frazier A, Djala I, Eli LD, Barnett B, Wildiers H. Memorial Sloan Kettering Cancer Center, New York, NY; Washington University School of Medicine, St. Louis, MO; City of Hope Comprehensive Cancer Center, Duarte, CA; UCLA, Santa Monica, CA; Fundación Instituto Valenciano de Oncología, Valencia, Spain; START Madrid-CIOCC, Hospital Universitario, Madrid Sanchinarro, Madrid, Spain; UT Southwestern Medical Center, Dallas, TX; Vanderbilt University Medical Center / Vanderbilt-Ingram Cancer Center, Nashville, TN; Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Alabama at Birmingham, Birmingham, AL; Hospital Clínico San Carlos, Madrid, Spain; Institut Curie, St. Cloud, France; St. Vincent's University Hospital, Dublin, Ireland; Puma Biotechnology Inc., Los Angeles, CA; University Hospitals Leuven, Leuven, Belgium.

11:15 AM CT BREAK

10:00 AM - 5:00 PM CT
EXHIBITS – Hall 2

11:30 AM - 12:30 PM CT
DEBATE – Hall 3

One Week of Whole Breast RT is the New Standard of Care

Chair: Wendy A. Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

Pro

Charlotte E. Coles, MbChB, PhD
University of Cambridge
Cambridge, United Kingdom

Con

Julia White, MD
Ohio State University
Columbus, OH

12:30 PM - 1:00 PM CT

AACR Outstanding Investigator Award for Breast Cancer Research – Hall 3

Fabrice Andre, MD, PhD
Gustave Roussy
Villejuif, France

1:00 PM - 1:30 PM CT
BREAK

1:30 PM - 2:30 PM CT
PLENARY LECTURE – Hall 3

Triple Negative Breast Cancer - Pitfalls and Progress

Lisa A. Carey, MD, ScM, FASCO
University of North Carolina at Chapel Hill
Chapel Hill, NC

2:00 PM - 3:00 PM CT
MINI SYMPOSIA

DNA Repair in Breast Cancer - Diagnosis and Treatment – Stars at Night Ballroom 1&2

Moderator: Simon N. Powell, MD, PhD, FRCP
Memorial Sloan Kettering Cancer Center
New York, NY

CRISPR screens to identify novel DNA repair defects synthetic lethal therapies

Daniel Durocher, PhD
Lunefeld-Tanenbaum Research Institute
Toronto, Canada

Genomics of DNA repair defects in breast cancer

Serena Nik-Zainal, PhD
University of Cambridge
Cambridge, United Kingdom

Targeting DNA damage response and HRD in breast cancer

Timothy A. Yap, MBBS, PhD, FRCP
UT MD Anderson Cancer Center
Houston, TX

The Evolution of Local Therapy in the Genomic Era – Hall 3

Moderator: Tari King, MD
Brigham and Women's Hospital
Boston, MA

Is less (or more) axillary surgery needed in the genomic era?

Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Can genomic risk be used to tailor radiation therapy?

Philip Poortmans, PhD
Iridium Netwerk
Paris, France

3:00 PM - 5:00 PM CT

YEAR IN REVIEW – Hall 3

Moderator: Carlos L. Arteaga, MD
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern
Dallas, TX

Basic science

Xiang Zhang, PhD
Baylor School of Medicine
Houston, TX

Translational research

Christina Curtis, PhD, MSc
Stanford Medicine
Stanford, CA

Early breast cancer

Foluso Olabisi Ademuyiwa, MD, MPH, MSCI
Washington University School of Medicine
Saint Louis, MO

Advanced breast cancer

Peter Schmid, MD, PhD
Bart's Cancer Institute Queen Mary University of London
London, United Kingdom

5:00 PM - 7:00 PM CT

View from the Trenches: What will You do on Monday Morning? – Stars at Night Ballroom 1&2

Co-Moderator: Stephen Johnston, MBBS, ARCP, PhD
The Royal Marsden Hospital
London, United Kingdom
and

Co-Moderator: Alastair Thompson, BSc (Hons), MBChB, MD, FRCSEd, FACS
Baylor College of Medicine
Houston, MD

Panel Members

Carlos H. Barrios, MD
Latin American Cooperative Oncology Group (LACOG)
Porto Alegre, Brazil

Thomas Braun, PhD
University of Michigan
Ann Arbor, MI

Javier Cortes, MD, PhD
International Breast Cancer Center
Barcelona, Spain

Erika Hamilton, MD
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

Meena Moran, MD
Yale School of Medicine
New Haven, CT

Ann H. Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Jorge S. Reis-Filho, MD, MRCPATH, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Ivis Febus-Sampayo
SHARE
New York, NY

Anna C. Weiss, MD
Brigham and Women's Hospital
Boston, MA

7:00 PM CT

OPEN SATELLITE EVENT - San Antonio Marriott Rivercenter

Molecular Imaging and Breast Cancer: Selecting and Evaluating Targeted Treatments presented by Society of Nuclear Medicine and Molecular Imaging SNMMI

Register for this complimentary live symposia or virtual event:
<http://www.snmmi.org/sabcs>.